Today Biogen stock is discussed ahead of the open, but recent session figures and a dated Nasdaq clo

Biogen Inc. stock is trading close to its 12 month high as investors weigh stable Q1 2026 revenue gr

Biogen (BIIB) target price: $292.97 (32.3% upside). Current price: $221.39. See our analyst rating, optimistic/conservative scenarios, and 5-year forecast.

Stoke Therapeutics and Biogen reported long-term zorevunersen data showing seizure reductions and cognitive improvements in Dravet syndrome studies.

Biogen stock is supported by a Piper Sandler target increase to USD 245 after the firm kept an Overw

–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines– –New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)– –Improvements in quality of life were demonstrated through 28 months of treatment– –Zore

Quality of life improvements were demonstrated through 28 months, while 77% of patients remained in four-year extension studies; Phase 3 data are anticipated in Q3 2027.

Biogen Inc. stock is trading above 219 USD as investors weigh fresh Canadian support for Alzheimer d